Additionally, the 36-month beta value for BBIO is 0.71. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average price predicted by analysts for BBIO is $28.60, which is $15.13 above the current price. The public float for BBIO is 107.05M and currently, short sellers hold a 12.42% ratio of that float. The average trading volume of BBIO on May 26, 2023 was 3.20M shares.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
BBIO) stock’s latest price update
The stock of BridgeBio Pharma Inc. (NASDAQ: BBIO) has increased by 1.88 when compared to last closing price of 13.29.Despite this, the company has seen a loss of -3.15% in its stock price over the last five trading days. Barron’s reported on 12/28/21 that BridgeBio Rallies After Its Worst Trading Day. Stocktwits Mentions Are Rising.
BBIO’s Market Performance
BridgeBio Pharma Inc. (BBIO) has experienced a -3.15% fall in stock performance for the past week, with a -5.25% drop in the past month, and a 16.22% rise in the past quarter. The volatility ratio for the week is 5.57%, and the volatility levels for the past 30 days are at 6.02% for BBIO. The simple moving average for the past 20 days is -2.90% for BBIO’s stock, with a 18.84% simple moving average for the past 200 days.
BBIO Trading at -7.58% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.11% of loss for the given period.
Volatility was left at 6.02%, however, over the last 30 days, the volatility rate increased by 5.57%, as shares sank -4.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.98% lower at present.
During the last 5 trading sessions, BBIO fell by -3.15%, which changed the moving average for the period of 200-days by +22.09% in comparison to the 20-day moving average, which settled at $13.91. In addition, BridgeBio Pharma Inc. saw 77.69% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BBIO starting from Kumar Neil, who sale 51,552 shares at the price of $14.01 back on May 17. After this action, Kumar Neil now owns 4,813,197 shares of BridgeBio Pharma Inc., valued at $722,218 using the latest closing price.
STEPHENSON BRIAN C, the Secretary, Treasurer & CFO of BridgeBio Pharma Inc., sale 24,424 shares at $14.01 during a trade that took place back on May 17, which means that STEPHENSON BRIAN C is holding 36,408 shares at $342,168 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -603.28 for the present operating margin
- +89.95 for the gross margin
The net margin for BridgeBio Pharma Inc. stands at -619.70. The total capital return value is set at -69.88, while invested capital returns managed to touch -73.05. Equity return is now at value 36.60, with -59.90 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 43.03, with the company’s debt to enterprise value settled at 0.73. The receivables turnover for the company is 4.22 and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.52.
In conclusion, BridgeBio Pharma Inc. (BBIO) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.